Intermediate vancomycin susceptibility in a community-associated MRSA clone

Emerg Infect Dis. 2007 Mar;13(3):491-3. doi: 10.3201/eid1303.060960.

Abstract

We describe a case of treatment failure caused by a strain of USA300 community-associated methicillin-resistant Staphylococcus aureus (MRSA) with intermediate susceptibility to vancomycin and reduced susceptibility to daptomycin. The strain was isolated from the bone of a 56-year-old man with lumbar osteomyelitis after a 6-week treatment course of vancomycin for catheter-associated septic thrombophlebitis.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / microbiology
  • Daptomycin / pharmacology
  • Humans
  • Lumbar Vertebrae / microbiology
  • Male
  • Methicillin / pharmacology*
  • Methicillin Resistance
  • Microbial Sensitivity Tests
  • Middle Aged
  • Osteomyelitis / drug therapy
  • Osteomyelitis / microbiology
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / microbiology*
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / isolation & purification
  • Thrombophlebitis / drug therapy
  • Treatment Outcome
  • Vancomycin / pharmacology*
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Vancomycin
  • Daptomycin
  • Methicillin